Equities Analysts Set Expectations for Lexeo Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Leerink Partnrs issued their FY2027 earnings estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($2.58) per share for the year. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.03) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2028 earnings at $0.12 EPS.

Lexeo Therapeutics Stock Down 2.7 %

Shares of NASDAQ LXEO opened at $12.16 on Thursday. Lexeo Therapeutics has a 12-month low of $9.00 and a 12-month high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.21 and a quick ratio of 7.21. The company’s 50-day simple moving average is $14.37.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.15).

Institutional Trading of Lexeo Therapeutics

Hedge funds have recently made changes to their positions in the company. Blackstone Inc. purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $9,342,000. Omega Fund Management LLC purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $28,955,000. Finally, Eventide Asset Management LLC purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $40,298,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.